Costimulation Blockade Disrupts CD4⁺ T Cell Memory Pathways and Uncouples Their Link to Decline in β-Cell Function in...

Area of Science:

• Immunology
• Endocrinology
• Type 1 Diabetes Research

Background:

• Previous studies showed abatacept limits beta-cell decline and central memory T cell (TCM) loss in new-onset type 1 diabetes (T1D).
• An association was observed between increased CD4+ TCM cells and declining beta-cell function in placebo-treated T1D patients.

Purpose of the Study:

• To investigate changes in CD4+ and CD8+ naive and memory T cell subsets with higher resolution in new-onset T1D.
• To further elucidate the mechanism of action of abatacept in T1D by examining its effects on T cell subsets and their relationship with beta-cell function.

Main Methods:

• Utilized polychromatic flow cytometry and mass cytometry for high-resolution analysis of T cell subsets.
• Analyzed changes in CD4+ and CD8+ T cell populations (naive, memory, regulatory) in T1D patients receiving abatacept or placebo.

Main Results:

• Confirmed the association between TCM cells and beta-cell function decline in placebo group; extended findings to other T cell subsets.
• Abatacept significantly altered CD4+ T cell subsets, increasing Ag-naive and decreasing Ag-experienced subsets.
• CD8+ T cell subsets showed relative resistance to abatacept, suggesting lower CD28 dependence. Abatacept uncoupled the natural history relationship between T cell changes and beta-cell function.

Conclusions:

• Abatacept modifies T cell subset frequencies in T1D, impacting the natural history of the disease.
• The observed uncoupling of T cell dynamics and beta-cell function by abatacept suggests a novel immunotherapy mechanism.
• Immunological markers predicting beta-cell function decline are not predictive for abatacept therapy due to this drug-induced uncoupling.